We previously demonstrated that BCR-ABL1-positive leukemia cells, which are clinically sensitive to the GVL effect [12] frequently express DR4 and/or DR5, and, subsequently, are sensitive to anti-leukemic activity of recombinant human soluble TRAIL (rhsTRAIL) [13]. This evidence concerns the gene TNFSF10 and leukemia.